PIK3CA: a Target or a Marker in Breast Cancers

Maria Vittoria Dieci, Valentina Guarneri

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The phosphoinositide 3 kinase (PI3K)/Akt pathway is frequently aberrantly activated in breast cancer and, basing on preclinical data, leads to cell growth and tumor proliferation. PI3K pathway activation has been suggested as a potential driver of resistance to endocrine and anti-HER2 therapies. Large genomic studies have observed that the PIK3CA gene is mutated in up to 40 % of breast cancers, mainly estrogen receptor- and HER2-positive. Some strategies targeting the PI3K/Akt/mTOR axis, in particular co-targeting the estrogen receptor and mTOR in endocrine resistant estrogen receptor-positive breast cancer, have proven successfully this hypothesis. Pan-class I PI3K inhibitors and more selective p110α inhibitors are currently under investigation in different clinical settings. In this review, clinical data on the prognostic and predictive role of PIK3CA mutations in different breast cancer subtypes are covered, and a picture on the current clinical research on PI3K inhibitors is provided.

Original languageEnglish
Pages (from-to)161-169
Number of pages9
JournalCurrent Breast Cancer Reports
Volume7
Issue number3
DOIs
Publication statusPublished - Sep 24 2015

Fingerprint

1-Phosphatidylinositol 4-Kinase
Breast Neoplasms
Estrogen Receptors
Mutation
Growth
Research
Genes
Neoplasms

Keywords

  • Breast cancer
  • PI3K
  • PIK3CA
  • Predictive factor

ASJC Scopus subject areas

  • Oncology

Cite this

PIK3CA : a Target or a Marker in Breast Cancers. / Dieci, Maria Vittoria; Guarneri, Valentina.

In: Current Breast Cancer Reports, Vol. 7, No. 3, 24.09.2015, p. 161-169.

Research output: Contribution to journalArticle

Dieci, Maria Vittoria ; Guarneri, Valentina. / PIK3CA : a Target or a Marker in Breast Cancers. In: Current Breast Cancer Reports. 2015 ; Vol. 7, No. 3. pp. 161-169.
@article{804737c8dc44455ca457f03112e4c318,
title = "PIK3CA: a Target or a Marker in Breast Cancers",
abstract = "The phosphoinositide 3 kinase (PI3K)/Akt pathway is frequently aberrantly activated in breast cancer and, basing on preclinical data, leads to cell growth and tumor proliferation. PI3K pathway activation has been suggested as a potential driver of resistance to endocrine and anti-HER2 therapies. Large genomic studies have observed that the PIK3CA gene is mutated in up to 40 {\%} of breast cancers, mainly estrogen receptor- and HER2-positive. Some strategies targeting the PI3K/Akt/mTOR axis, in particular co-targeting the estrogen receptor and mTOR in endocrine resistant estrogen receptor-positive breast cancer, have proven successfully this hypothesis. Pan-class I PI3K inhibitors and more selective p110α inhibitors are currently under investigation in different clinical settings. In this review, clinical data on the prognostic and predictive role of PIK3CA mutations in different breast cancer subtypes are covered, and a picture on the current clinical research on PI3K inhibitors is provided.",
keywords = "Breast cancer, PI3K, PIK3CA, Predictive factor",
author = "Dieci, {Maria Vittoria} and Valentina Guarneri",
year = "2015",
month = "9",
day = "24",
doi = "10.1007/s12609-015-0184-1",
language = "English",
volume = "7",
pages = "161--169",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - PIK3CA

T2 - a Target or a Marker in Breast Cancers

AU - Dieci, Maria Vittoria

AU - Guarneri, Valentina

PY - 2015/9/24

Y1 - 2015/9/24

N2 - The phosphoinositide 3 kinase (PI3K)/Akt pathway is frequently aberrantly activated in breast cancer and, basing on preclinical data, leads to cell growth and tumor proliferation. PI3K pathway activation has been suggested as a potential driver of resistance to endocrine and anti-HER2 therapies. Large genomic studies have observed that the PIK3CA gene is mutated in up to 40 % of breast cancers, mainly estrogen receptor- and HER2-positive. Some strategies targeting the PI3K/Akt/mTOR axis, in particular co-targeting the estrogen receptor and mTOR in endocrine resistant estrogen receptor-positive breast cancer, have proven successfully this hypothesis. Pan-class I PI3K inhibitors and more selective p110α inhibitors are currently under investigation in different clinical settings. In this review, clinical data on the prognostic and predictive role of PIK3CA mutations in different breast cancer subtypes are covered, and a picture on the current clinical research on PI3K inhibitors is provided.

AB - The phosphoinositide 3 kinase (PI3K)/Akt pathway is frequently aberrantly activated in breast cancer and, basing on preclinical data, leads to cell growth and tumor proliferation. PI3K pathway activation has been suggested as a potential driver of resistance to endocrine and anti-HER2 therapies. Large genomic studies have observed that the PIK3CA gene is mutated in up to 40 % of breast cancers, mainly estrogen receptor- and HER2-positive. Some strategies targeting the PI3K/Akt/mTOR axis, in particular co-targeting the estrogen receptor and mTOR in endocrine resistant estrogen receptor-positive breast cancer, have proven successfully this hypothesis. Pan-class I PI3K inhibitors and more selective p110α inhibitors are currently under investigation in different clinical settings. In this review, clinical data on the prognostic and predictive role of PIK3CA mutations in different breast cancer subtypes are covered, and a picture on the current clinical research on PI3K inhibitors is provided.

KW - Breast cancer

KW - PI3K

KW - PIK3CA

KW - Predictive factor

UR - http://www.scopus.com/inward/record.url?scp=84940182413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940182413&partnerID=8YFLogxK

U2 - 10.1007/s12609-015-0184-1

DO - 10.1007/s12609-015-0184-1

M3 - Article

AN - SCOPUS:84940182413

VL - 7

SP - 161

EP - 169

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 3

ER -